Spark Therapeutics Files Registration Statement for Initial Public Offering

News provided by

Dec 31, 2014, 08:00 ET

PHILADELPHIA, Dec. 31, 2014 /PRNewswire/ -- Spark Therapeutics announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Spark has applied to list its common stock under the symbol "ONCE" on The NASDAQ Global Market.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC will act as lead book-running managers for the offering. Cowen and Company LLC will act as lead manager and Sanford C. Bernstein & Co., LLC will act as co-manager.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, by facsimile at (212) 325-8057, or by email at [email protected].

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Spark Therapeutics

Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spark-therapeutics-files-registration-statement-for-initial-public-offering-300014716.html

SOURCE Spark Therapeutics